OCTOBER, 20258TOP STORIESTOP STORIESDANFOSS INDIA LAUNCHES MADE-IN-INDIA STL VALVESFOR COLD CHAINCII, ICON LEAD TALKS ON INDIA PHARMA PUSH INTO US MANUFACTURINGDanfoss India, a wholly owned subsidiary of the Danfoss Group, which is based in Denmark, announced the introduction of its "Made in India" STL family of refrigeration valves that are specially designed for the cold chain sector. The valves are produced at the company's Oragadam facility, located near Chennai, under the Government of India's `Make in India' initiative.The company also said that the new STL valves are conceptualized for minimizing food wastage, increasing the farmers' income, and building up the supply chain's sustainability. As fruits and vegetables, milk, meat, and fish are becoming perishable, the technology is expected to take over the role of India's cold storage infrastructure by facilitating the efficient preservation of these items.Madhur Sehgal, managed Sales, Climate Solutions, Danfoss India Region, said, "A leap in refrigeration valve technology, designed and manufactured in India to meet the needs of the country's rapidly growing cold-chain industry." He also mentioned the installation, service, and testing aspects that are made easier by the product's modularity, and service-friendly design, which help operators gain time, lower energy use and increase system life.The significance of the introduction was acknowledged by Ravichandran Purushothaman, President of Danfoss India Region and Chairman, CII National Committee on Cold Chain, said, "The STL valve family is a revolutionary idea that provides solutions made to global standards in India. This will be the real support to food security by cutting wastage of produce and ensuring a sustainable nature of the cold-chain ecosystem through less energy and better performance."The STL valve family that comes with guaranteed local manufacturing, quicker service support, and long-term operational benefits is positioned to be the boon to cold storages in warehousing and multi-commodity storage facilities all over India. Sanjay Singh, Past Chairman, CII Telangana and Chakravarthi AVPS, Convener, CII Telangana Pharma and Life Sciences Panel & Chairman & MD, Ecobliss India Pvt. Ltd. emphasized the above average presence of resilience, competitiveness, etc. and also the sector's need to change its approach with the latest geopolitical and regulatory upheavals.Bhupendra Patel, ICON's CEO, and Founder, stated once more that the company is always committed to accommodating the pharma and biotech clients with high-tech, affordable US facilities. He also added that through their 30-plus years of experience and 200 plus completed projects, over which a total of $300 million has been invested, ICON should be able to provide the required biopharmaceutical manufacturing solutions in full scope.The event with a keynote speech by Venugopal Rao Sankineni, Vice President, Medical Devices Policy & Investments, Telangana Lifesciences, also put forward the idea that Telangana might be a very good choice for pharma and medtech startups with plans to grow at the global level.One of the most attractive parts of the event was the launch of the whitepaper "Changing Landscape: Indian Pharma's Move Toward US-Based Manufacturing" prepared by ICON and CII with Healthark as the knowledgeable partner. US-based construction company ICON, in collaboration with the Confederation of Indian Industry (CII) Telangana, has successfully brought the PharmiCON, its pioneering event in India, to Hyderabad.The event was held under the theme "Navigating the Road Ahead for US-Based Manufacturing" and was targeted to senior industry leaders, policy experts, and business stakeholders to discuss the opportunities and challenges of Indian pharmaceutical manufacturing expansion into the United States.
< Page 7 | Page 9 >